Below is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.
All News
Article
Article
Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?
Article
A large US population based study shows that psoriasis is associated with a higher risk of nonalcoholic fatty liver disease (NAFLD).
Aurelie Najm
Tweet
AxSpA and AxPsA 2 sides of the same coin or 2 different diseases? Divergent IL-23i efficacy data seem to suggest the latest.
German GESPIC AxPsA cohort:
*More frequently 🚺
*Less frequently B27+
*20% isolated Ax involvement
@Rheumnow OP0026 #EULAR2022 https://t.co/FZP9nEyG7J
Richard Conway
Tweet
More from the VITAL study Dr Costenbader @karen_kc123 et al. 5 year supplementation followed 2 year follow up. Vit D 2000iu ⬇️incident autoimmune disease 21%. RA, PMR, psoriasis trend towards reduction. No effect omega-3 @RheumNow #EULAR2022 OP0038 https://t.co/kbKqDhtN9z https://t.co/HcFXbweEPm
David Liew
Tweet
in case you're interesting in the causal diagram for the mediation modelling for this:
far from proven, but certainly does raise some questions about a potential advantage of IL-23 inhibitors in a crowded PsA market #EULAR2022 @RheumNow https://t.co/bSuE3tDHUO
Janet Pope
Tweet
#What’sHot? Axial PsA cohort as some drugs seem to work differently in axPsA vs axSpA Less HLAB27+, less male, 17% isolated axial in PsA #OP0026 @RheumNow #EULAR2022 @eular_org https://t.co/I0azSymVrr
David Liew
Tweet
Minimal disease activity achivement by PsA domain over 2y, in guselkumab phase 3
Everyone goes on about skin efficacy with guselkumab, but pretty good early on for enthesitis & swollen joints too... has challenged my uninformed thinking!
POS1067 #EULAR2022 #IL23 @RheumNow https://t.co/chCWeFd05o
Aurelie Najm
Tweet
🔜 Remission in PsA : the earlier the better ⏰
Dutch cohort (DEPAR) 300+pts
Failure to achieve MDA 1yr post diagnosis
🧨worst QoL yr 1️⃣2️⃣&3️⃣
🧨↗️bioDMARDs use over time
🧨no recovery
#OP0028 #EULAR2022 @RheumNow https://t.co/IS6ySIQvBP
Janet Pope
Tweet
Can you train #dermatologists to do ultrasound to detect #PsA if pt has joint pain. POCUS of up to 3 painful joints. US ⬆️derm suspicion of PsA- but this is not feasible in busy offices and no reimbursement @RheumNow #EULAR2022 @eular_org OP0029 https://t.co/9a3gDgIBp0
How do we treat fatigue in our PsA patients? Guselkumab PsA trials showed systemic disease activity/function, joint manifestations, and skin involvement accounted for 62% of variability in fatigue. How do we account for the other 38%?
@RheumNow #EULAR2022 ABST#OP0025
Janet Pope
Tweet
#Bestinclass #EULAR2022 #PsA @RheumNow #OP0027 #CVE #MACE with #Tofacitinib in #psoriatic #arthritis and #PsO with median 3 to 4 yrs Rx. 40% metabolic syndrome which is high. There was no comparison. As expected hose with ⬆️MACE risks had more outcomes. https://t.co/sTjFHsUxzi
Richard Conway
Tweet
Rahman et al. Factors associated with fatigue and its improvement in trials IL23i guselkumab. Disease activity/function (34%), joints (16%), skin (12%) but 38.5% of fatigue variability remains unexplained. @RheumNow #EULAR2022 OP0025 https://t.co/C08R0IWM3S https://t.co/QnCvPwEwKS
Looking forward to reading/watching the coverage of #EULAR2022 by our outstanding faculty, including Drs., Rachel Tate @uptoTate, Kathryn Dao @KDAO2011,
Robert Chao @doctorRBC , Janet Pope @Janetbirdope and Antoni Chan @synovialjoints . https://t.co/oBQCxzdzfF
To TDM or Not in Rheumatology?
Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists. But now, EULAR has a recommendation...
https://t.co/u86Vd8bFGr
#MedEdTwitter https://t.co/IpKqPoWM9R
Laurent ARNAUD
Tweet
🆒 Current indications for #biologics, in inflammatory rheumatic diseases 🔎 such as rheumatoid #arthritis, axSPA, PsA etc... A useful checklist ✅ to keep in the pocket prepared with
@DocFelten #Rheumatology #EULAR2022 https://t.co/cfc4VaF6GZ
It's our 8th year covering this important meeting! Join us June 1 - 4 for key opinion leader perspectives, clinical trial highlights and more, as we cover #EULAR2022. https://t.co/eHziBN3TWk
May 2022 EMA meeting the CHMP recommended new indications for Cosentyx (juvenile PsA, Enthesitis-related arthritis), Olumiant (alopecia areata), Rinvoq (ulcerative colitis) and Xeljanz (ankylosing spondylitis). EMA approval pending https://t.co/KauDY6e8zS https://t.co/mmv4G9jHI7
Biologic Persistence in Psoriatic Arthritis and Psoriasis
Recent studies examined the durability and persistence of biologic agents in patients with PSO and PsA and while some differences were noted overall persistence was low 3 years later.
https://t.co/sqxVaLnXEY https://t.co/yUPWYkRxva
